The FDA granted Moderna’s RSV vaccine candidate Breakthrough Therapy Designation Monday. 

The updated COVID-19 boosters from Pfizer Inc./BioNTech SE and Moderna helped prevent symptomatic infections against the new XBB-related subvariants, offering new evidence of how the vaccines perform against these fast-spreading strains, U.S. officials said today.

Moderna announced positive topline results from a Phase III trial with older adults and a vaccine candidate aimed at preventing respiratory syncytial virus.

Moderna chief executive Stephane Bancel said on Wednesday the U.S. company was in active discussions to supply COVID-19 vaccines to China but gave no further details.

Moderna entered into a collaboration/licensing agreement Thursday with oncology-focused CytomX to discover and develop conditionally activated mRNA therapies for cancer. 

Moderna Inc. on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker’s messenger RNA (mRNA) manufacturing capabilities.

The facility, which is expected to start producing shots in 2025, will provide patients in Britain access to domestically manufactured mRNA respiratory shots, including the company’s COVID vaccine that can protect against multiple variants.

A combination of Moderna’s melanoma vaccine and Merck’s immunotherapy Keytruda cut the risk of skin cancer’s recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.

The U.S. Food and Drug Administration on Thursday authorized updated COVID-19 booster shots from Moderna and Pfizer and its partner BioNTech for children as young as 6 months of age.

Britain’s health regulator on Tuesday authorized a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating the country’s youngest children once the UK’s Joint Committee on Vaccination and Immunization (JCVI) agrees.